Express News | FDA Approves Cosibelimab-Ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma - Website

BreakingsDec 14 07:03

Lake Street Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Raises Target Price to $7

Futu News59minutes ago · Ratings

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection

Benzinga22:22

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

WSJDec 14 08:09

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (Cosibelimab-ipdl)

GlobeNewswireDec 14 07:15

Express News | FDA: Approval of Cosibelimab-Ipdl (Unloxcyt) Granted to Checkpoint Therapeutics

BreakingsDec 14 07:04